Pixantrone

• CAT Number: I001709
• CAS Number: 144510-96-3
• Molecular Formula: C17H19N5O2
• Molecular Weight: 325.37
• Purity: ≥95%
• Target: Topoisomerase
• Solubility: 10 mM in DMSO
• Storage: -20°C
• IUPAC Name: 6,9-bis(2-aminoethylamino)benzo[g]isoquinoline-5,10-dione
• InChI: InChI=1S/C17H19N5O2/c18-4-7-21-12-1-2-13(22-8-5-19)15-14(12)16(23)10-3-6-20-9-11(10)17(15)24/h1-3,6,9,21-22H,4-5,7-8,18-19H2
• InChIKey: PEZPMAYDXJQYRV-UHFFFAOYSA-N
• SMILES: C1=CC(=C2C(=C1NCCN)C(=O)C3=C(C2=O)C=NC=C3)NCCN

Pixantrone（Cat No.:I001709）is an investigational anthraquinone-based chemotherapy drug used in the treatment of hematologic cancers, particularly refractory or relapsed non-Hodgkin lymphoma (NHL). It functions as a topoisomerase II inhibitor, interfering with DNA replication and repair, ultimately leading to cancer cell death. Unlike traditional anthracyclines, pixantrone has a modified structure, which is believed to reduce cardiotoxicity while retaining its antitumor activity. It has been evaluated in clinical trials, showing potential efficacy in lymphoma treatment, especially in patients who have not responded to other therapies. Pixantrone is not yet approved for widespread clinical use.

Reference

[1]. Cavalletti, E., et al., Pixantrone (BBR 2778) has reduced cardiotoxic potential in mice pretreated with doxorubicin: comparative studies against doxorubicin and mitoxantrone. Invest New Drugs, 2007. 25(3): p. 187-95.

[2]. Evison, B.J., et al., Pixantrone can be activated by formaldehyde to generate a potent DNA adduct forming agent. Nucleic Acids Res, 2007. 35(11): p. 3581-9.